Prepare for a swine health revolution! Merck Animal Health has just unveiled a groundbreaking vaccine that's set to transform the industry. Say hello to Sequivity with Microsol Diluvac Forte (MDF) adjuvant, the latest weapon in the fight against swine diseases.

This cutting-edge vaccine harnesses the power of RNA Particle Technology, a game-changing innovation that promises safe, flexible, and precise protection for gilts and sows. By combining the trusted MDF adjuvant with the Sequivity platform, Merck has created a dynamic duo capable of addressing the unique needs of specific herds.

But that's not all – the Sequivity technology isn't just another vaccine. It's a rapid and targeted production platform that can tackle a wide range of viral and bacterial pathogens in swine. Unlike traditional vaccines that take years to develop, Sequivity delivers solutions in record time, thanks to its immuno-precision capabilities.

Jeremy Maurer, V.M.D., Associate Director of U.S. Livestock Insights and Outcomes for Merck Animal Health, is thrilled about the potential of this groundbreaking vaccine. "We are excited to offer a new vaccine with an adjuvant using our Sequivity technology," he says. "It's all supported by our web-based Sequivity dashboard to help swine producers and veterinarians make data-driven decisions."

But how does it work? The vaccine comes in two bottles – a frozen antigen bottle and a diluent bottle – that are mixed at the point of use, ensuring freshness and potency.

With Sequivity with MDF adjuvant, Merck is not just raising the bar – they're rewriting the playbook for swine health. Get ready for a new era of protection and performance in pig farming!